The latest price target for Climb Bio (NASDAQ:CLYM) was reported by Mizuho on April 15, 2026. The analyst firm set a price target for $18.00 expecting CLYM to rise to within 12 months (a possible 91.90% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for Climb Bio (NASDAQ:CLYM) was provided by Mizuho, and Climb Bio initiated their outperform rating.

There is no last upgrade for Climb Bio

There is no last downgrade for Climb Bio.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Climb Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Climb Bio was filed on April 15, 2026 so you should expect the next rating to be made available sometime around April 15, 2027.

While ratings are subjective and will change, the latest Climb Bio (CLYM) rating was a initiated with a price target of $0.00 to $18.00. The current price Climb Bio (CLYM) is trading at is $9.38, which is within the analyst’s predicted range.